Emerging as a promising advance in the battle against excess weight, Retatrutide is quickly gaining attention. This new dual agonist – targeting both GLP-1 and GIP receptors – demonstrates remarkable efficacy in research studies. Early information indicate that Retatrutide might provide enhanced